EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 172 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.91 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $601,000 | +8485.7% | 10,000 | +7252.9% | 0.02% | – |
| Q1 2019 | $7,000 | -41.7% | 136 | -52.9% | 0.00% | -100.0% |
| Q4 2018 | $12,000 | +33.3% | 289 | +112.5% | 0.00% | 0.0% |
| Q3 2018 | $9,000 | -96.5% | 136 | -96.0% | 0.00% | -93.8% |
| Q2 2018 | $258,000 | +41.8% | 3,407 | 0.0% | 0.02% | +6.7% |
| Q4 2017 | $182,000 | -24.2% | 3,407 | -15.2% | 0.02% | -31.8% |
| Q3 2017 | $240,000 | +15.9% | 4,018 | +53.5% | 0.02% | +10.0% |
| Q2 2017 | $207,000 | -20.1% | 2,618 | -19.7% | 0.02% | -35.5% |
| Q4 2016 | $259,000 | +66.0% | 3,260 | +46.2% | 0.03% | +93.8% |
| Q3 2016 | $156,000 | +15500.0% | 2,230 | +2130.0% | 0.02% | – |
| Q3 2014 | $1,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |